See more : Blue Foundry Bancorp (BLFY) Income Statement Analysis – Financial Results
Complete financial analysis of Lipella Pharmaceuticals Inc. (LIPO) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Lipella Pharmaceuticals Inc., a leading company in the Biotechnology industry within the Healthcare sector.
You may be interested
- Attune RTD, Inc (AURT) Income Statement Analysis – Financial Results
- Castillo Copper Limited (CCZ.L) Income Statement Analysis – Financial Results
- Euroafrica Digital Ventures AB (publ) (EURA.ST) Income Statement Analysis – Financial Results
- Nokian Renkaat Oyj (NKRKF) Income Statement Analysis – Financial Results
- Aleafia Health Inc. (AH.TO) Income Statement Analysis – Financial Results
Lipella Pharmaceuticals Inc. (LIPO)
About Lipella Pharmaceuticals Inc.
Lipella Pharmaceuticals Inc., a clinical-stage biotechnology company, focuses on developing drugs by reformulating the active agents in existing generic drugs and optimizing these reformulations for various applications. It is developing LP-10, a formulation of tacrolimus that is in Phase IIa clinical trial for patients with radiation-induced hemorrhagic cystitis; and LP-310, a formulation of tacrolimus for the treatment of oral lichen planus. The company was incorporated in 2005 and is based in Pittsburgh, Pennsylvania.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 |
|---|---|---|---|---|---|
| Revenue | 449.62K | 184.16K | 259.35K | 961.68K | 694.75K |
| Cost of Revenue | 3.04M | 2.55M | 1.46M | 975.96K | 682.89K |
| Gross Profit | -2.59M | -2.36M | -1.20M | -14.28K | 11.86K |
| Gross Profit Ratio | -575.87% | -1,283.43% | -461.71% | -1.48% | 1.71% |
| Research & Development | 3.04M | 2.55M | 1.46M | 975.96K | 682.89K |
| General & Administrative | 2.16M | 226.19K | 718.38K | 42.59K | 65.65K |
| Selling & Marketing | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 2.16M | 226.19K | 718.38K | 42.59K | 65.65K |
| Other Expenses | 0.00 | -45.00 | 57.09K | 0.00 | 0.00 |
| Operating Expenses | 2.16M | 2.77M | 2.18M | 1.02M | 748.54K |
| Cost & Expenses | 5.20M | 2.77M | 2.18M | 1.02M | 748.54K |
| Interest Income | 137.84K | 1.68K | 104.00 | 3.17K | 334.00 |
| Interest Expense | 10.85K | 9.61K | 6.83K | 7.97K | 8.39K |
| Depreciation & Amortization | 1.69K | 2.59M | 1.92M | 56.86K | 53.79K |
| EBITDA | -4.61M | -2.59M | 0.00 | -53.69K | 334.00 |
| EBITDA Ratio | -1,024.52% | -1,405.37% | -716.66% | -5.58% | -7.74% |
| Operating Income | -4.75M | -2.59M | -1.92M | -56.86K | -53.79K |
| Operating Income Ratio | -1,055.55% | -1,406.26% | -738.71% | -5.91% | -7.74% |
| Total Other Income/Expenses | 126.99K | -7.98K | 50.36K | -4.79K | -8.06K |
| Income Before Tax | -4.62M | -2.60M | -1.87M | -61.66K | -61.85K |
| Income Before Tax Ratio | -1,027.31% | -1,410.59% | -719.30% | -6.41% | -8.90% |
| Income Tax Expense | 0.00 | -1.63K | 6.73K | 4.79K | -53.79K |
| Net Income | -4.62M | -2.60M | -1.87M | -66.45K | -61.85K |
| Net Income Ratio | -1,027.31% | -1,409.71% | -721.89% | -6.91% | -8.90% |
| EPS | -0.77 | -0.45 | -0.33 | -0.01 | -0.01 |
| EPS Diluted | -0.77 | -0.45 | -0.33 | -0.01 | -0.01 |
| Weighted Avg Shares Out | 6.00M | 5.74M | 5.74M | 5.69M | 5.69M |
| Weighted Avg Shares Out (Dil) | 6.00M | 5.74M | 5.74M | 5.69M | 5.69M |
Lipella Pharmaceuticals Announces FDA Clearance of IND for LP-410 for Oral Graft-Versus-Host Disease, Advancing Clinical Pipeline
PITTSBURGH, March 05, 2024 (GLOBE NEWSWIRE) -- Lipella Pharmaceuticals Inc. (Nasdaq: “LIPO”) (“Lipella,” “our, “us” or the “Company”), a clinical-stage biotechnology company addressing serious diseases with significant unmet need, today announces that the U.S. Food and Drug Administration (FDA) has...
Lipella Pharmaceuticals to Present at PropThink Digital Investor Conference
Chief Medical Officer Dr. Michael Chancellor will discuss hemorrhagic cystitis and the company's lead candidate, LP-10 Pittsburgh, PA, February 20, 2023 – Lipella Pharmaceuticals Inc. (Nasdaq: LIPO) (“Lipella,” “our,” “us” or the “Company”) a pioneering, clinical-stage pharmaceutical company, announced today...
Lipella Pharmaceuticals to Present at PropThink Digital Investor Conference
PITTSBURGH, Feb. 20, 2024 (GLOBE NEWSWIRE) -- Lipella Pharmaceuticals Inc., (Nasdaq: LIPO) ("Lipella," "our," "us" or the "Company"), a pioneering, clinical-stage pharmaceutical company, announced today that Chief Medical Officer Dr. Michael Chancellor will present at the PropThink Digital Investor Conference's...
PRISM MarketView: Biotech In Motion – Lipella Pharmaceuticals Celebrates Year of Success
New York, December 20, 2023 – Clinical-stage biotechnology company, Lipella Pharmaceuticals (Nasdaq: LIPO) is celebrating a year of strategic accomplishments on its first anniversary as a public company. Lipella is advancing three clinical indications and has been granted two Orphan Drug Designations by the...
Lipella Pharmaceuticals Marks Successful First Year with Strategic Progress and Key Milestones Accomplished
–Lipella Granted Two Orphan Drug Designations by FDA- Pittsburgh, PA, December 20, 2023 – Lipella Pharmaceuticals Inc. (Nasdaq: LIPO) (“Lipella,” “our,” “us” or the “Company”) a pioneering, clinical-stage pharmaceutical company, celebrates its first anniversary as a publicly traded entity.
Lipella Pharmaceuticals Marks Successful First Year with Strategic Progress and Key Milestones Accomplished
PITTSBURGH, Dec. 20, 2023 (GLOBE NEWSWIRE) -- Lipella Pharmaceuticals Inc., (Nasdaq: LIPO) ("Lipella," "our," "us" or the "Company"), a pioneering, clinical-stage pharmaceutical company, celebrates its first anniversary as a publicly traded entity. Based in Pittsburgh, PA, the Company has made...
Lipella Pharmaceuticals Granted FDA Orphan Designation for Oral Graft-versus-Host Disease Drug
“GvHD affects approximately 30,000 Americans and oral GvHD causes significant oral pain and discomfort, making it difficult for patients to eat, drink and speak. Oral GvHD is a great unmet need in cancer survivors.
FDA Grants Orphan Designation for Lipella's LP-310 Drug Candidate for Oral Graft-versus-Host Disease
Lipella Pharmaceuticals' LP-310 clinical stage asset is formulated for delivering active agents to the oral cavity for diseases of the mouth including oral lichen planus and oral graft-versus-host disease PITTSBURGH , Nov. 10, 2023 /PRNewswire/ -- Lipella Pharmaceuticals Inc. (Nasdaq: LIPO),...
Lipella Pharmaceuticals to Present at the Fall Foliage MicroCap Rodeo Conference
Pittsburgh, PA, October 23, 2023 – Lipella Pharmaceuticals Inc. (Nasdaq: LIPO) (“Lipella,” “our, “us” or the “Company”), a clinical-stage biotechnology company addressing serious diseases with significant unmet need, will present at the 2023 virtual Fall Foliage MicroCap Rodeo Conference to...
Lipella Pharmaceuticals stock more than doubles in 3 days as FDA approves IND for OLP treatment
Shares of Lipella Pharmaceuticals Inc. LIPO, +51.55% rocketed 52.2% higher in very active tracing Friday, after the Pittsburgh-based biotechnology company's investigational new drug application for its oral lichen planus treatment was approved by the U.S. Food and Drug Administration. Trading...
Source: https://incomestatements.info
Category: Stock Reports